Literature DB >> 16714161

Fixed-drug combinations as first-line treatment for hypertension.

Talma Rosenthal1, Irene Gavras.   

Abstract

As combinations of drugs from different classes that have synergistic or additive effect and properties to cancel out each others' untoward hemodynamic and metabolic effects become more and more widely used, their use as first-line therapy for the treatment of newly diagnosed hypertensive patients is growing in popularity as well. The possibility to begin therapy with a fixed 2-drug combination may be preferable to starting with monotherapy followed by upward titration and addition of other agents. More and more combinations are coming out on the market and proving their effectiveness in randomized controlled trials and in large multicenter studies. One suggestion is the "polypill," a fixed combination of multiple agents that address various components of the metabolic syndrome and coexisting common risk factors in both high-risk patients with conditions requiring polypharmacy, and in healthy asymptomatic individuals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16714161     DOI: 10.1016/j.pcad.2006.03.003

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  11 in total

Review 1.  Should two-drug initial therapy for hypertension be recommended for all patients?

Authors:  Jennifer B Cowart; Addison A Taylor
Journal:  Curr Hypertens Rep       Date:  2012-08       Impact factor: 5.369

Review 2.  Issues to consider in the pharmaceutical development of a cardiovascular polypill.

Authors:  Antonio Guglietta; Marta Guerrero
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-12-23

3.  Long-term persistence to mono and combination therapies with angiotensin converting enzymes and angiotensin II receptor blockers in Australia.

Authors:  Svetla Gadzhanova; Elizabeth E Roughead; Louise E Bartlett
Journal:  Eur J Clin Pharmacol       Date:  2016-03-10       Impact factor: 2.953

4.  Antihypertensive use before and after initiation of fixed-dose combination products in Australia: a retrospective study.

Authors:  Svetla Gadzhanova; Jenni Ilomäki; Elizabeth E Roughead
Journal:  Int J Clin Pharm       Date:  2013-05-16

Review 5.  Fixed-dose combinations as initial therapy for hypertension: a review of approved agents and a guide to patient selection.

Authors:  Bernard Waeber; François Feihl; Luis M Ruilope
Journal:  Drugs       Date:  2009       Impact factor: 9.546

6.  [Fixed drug combinations in hypertension: a budget impact analysis for the Spanish Health System on the marketing of a fixed combination of olmesartan/amlodipine].

Authors:  M Belén Ferro-Rey; Alex Roca-Cusachs; Antoni Sicras-Mainar; Carlos Alvarez-Martín; Marina de Salas-Cansado
Journal:  Aten Primaria       Date:  2011-01-08       Impact factor: 1.137

7.  24-hour efficacy and safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: the TRINITY ambulatory blood pressure substudy.

Authors:  Joseph L Izzo; Steven G Chrysant; Dean J Kereiakes; Thomas Littlejohn Iii; Suzanne Oparil; Michael Melino; James Lee; Victor Fernandez; Reinilde Heyrman
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-10-28       Impact factor: 3.738

8.  Polypill-friend or foe?

Authors:  Rakesh Kumar Rishi
Journal:  Indian J Pharmacol       Date:  2011-05       Impact factor: 1.200

9.  Development and validation of an rp-hplc method for simultaneous determination of Ramipril and Amlodipine in tablets.

Authors:  Shi-Ying Dai; Shi-Ting Qiu; Wei Wu; Chun-Mei Fu
Journal:  J Pharm Anal       Date:  2013-10-02

10.  The Pol-e-pill finally arrives.

Authors:  James A Levine; Ronald M Davis
Journal:  Diabetes       Date:  2008-07       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.